Results 181 to 190 of about 6,173,935 (359)
MicroRNA 196a contributes to the aggressiveness of esophageal adenocarcinoma through the MYC/TERT/NFκB axis
Molecular Oncology, EarlyView.mir‐196a promotes Esophagus Adenocarcinoma aggressiveness. On one hand, mir‐196a targets the valosin‐containing protein (VCP) mRNA, causing the accumulation of c‐MYC protein that leads to high amounts of TERT. On the other hand, mir‐196a targets the inhibitor of NFκB (NFKBIA).Jesús García‐Castillo, Carlos M. Martínez‐Cáceres, Manuel Bernabé‐García, Vicente Munitiz, David Ruiz de Angulo, Pascual Parrilla, Ángeles Ortiz, Luisa F. Martínez de Haro, María L. Cayuela +8 morewiley +1 more sourceHow to do a systematic review [PDF]
, 2018 Alex Pollock, Banks JL, Barnett-Page E, Barnett-Page E, Bastian H, Berge E, Bobath B, Boers M, Boger EJ, Booth A, Booth A, Borah R, Brazzelli M, Cahill LS, Carr JH, Chalmers I, Chalmers I, Craig P, Davies PM, Deeks JJ, Dixon-Woods M, Eivind Berge, Fain JA, Feigin VL, Ganann R, Garner P, Glasziou P, Gotzsche PC, Gough D, Gough D, Gough D, Green BN, Greenwood N, Grimshaw J, Guyatt GH, Guyatt GH, Harden A, Higgins JPT, Hoffmann TC, Hoffmann TC, Joanna Briggs Institute, Kastner M, Katrak P, Kirkham JJ, Kreis J, Langhorne P, Lees R, Levac D, Moher D, Moher D, Moher D, Morley RF, Pendlebury ST, Peoples H, PLoS Medicine Editors, Pollock A, Pollock A, Pollock A, Pollock A, Rathbone J, Riva JJ, Rowat A, Sackett DL, Santisteban L, Saunders DH, Silagy CA, Snilstveit B, Stroke Unit Trialists Collaboration, Stroup DF, Thomas J, Tong A, Tyson SF, Tyson SF, Vickrey BG, Waddington H, Wardlaw JM, Weir MC, Whiting PF, Wildridge V, Williamson PR, Wong G, Yaffe J +81 morecore +1 more sourceComprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.Yang Song, Ting Liu, Qishan Hao, Qiuyun Fang, Xiaoyuan Gong, Yan Li, Zheng Tian, Hui Wei, Min Wang, Jianxiang Wang, Tao Cheng, Yingchang Mi +11 morewiley +1 more sourceCirculating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman +17 morewiley +1 more sourceDose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment
Molecular Oncology, EarlyView.Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin +10 morewiley +1 more source